ADAMSTS13 activity and inhibitor profile-994

Test info

  
ADAMSTS13 activity and inhibitor profile
  
994
  
LAB994
  
MSO
  
Metalloprotease
Protease Activity Inhibitor for TTP
von Willebrand Factor Cleaving Protease
Microangiopathy
Thrombotic Microangiopathy
VWF protease activity and inhibitor
  
Testing begins with the ADAMTS-13 activity assay to evaluate the percent activity. If the ADAMTS-13 activity is less than 30%, an inhibitor screen will be performed to look for specific ADAMTS-13 inhibition. If specific inhibition is apparent, the titer of the inhibitor will be determined.
  

Assisting with the diagnosis of congenital or acquired thrombotic thrombocytopenic purpura

Specimen

  

Fasting preferred

Specimen must be collected prior to replacement therapy

  
Sodium citrate (Na cit) plasma
  

To obtain adequate sample volume please collect 2 tubes:

 

Lt blue Sodium citrate (Na Cit) - 2.7mL 

  
2 mL plasma in 2 plastic vials each containing 1 mL
  
  • Do not over or under fill tube as the ratio of anticoagulant to whole blood is critical

Coag – tube fill guidelines

  • Immediately following collection, mix sample thoroughly by gently inverting 8 - 10 times to prevent clotting
  
  1. Centrifuge 
  2. Transfer plasma into a plastic vial 
  3. Centrifuge a second time
  4. Aliquot plasma (one mL per aliquot) into two seperate screw cap transfer vial/tube (Mayo T914), leaving 0.25 mL in the bottom of the centrifuged vial
  5. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, below -40 degrees C.
  
  

Frozen (strict) - 14 days

Refrigerated - NO

Ambient - NO

  
7 days

Performance

  
Mayo Clinic Laboratories (ADM13): R-NX
  
Mo - Fr, Su
  
3 days
  

Fluorescence Resonance Energy Transfer (FRET)

Clinical and Interpretive info

  

ADAMTS13 ACTIVITY ASSAY: > or =70%

ADAMTS13 INHIBITOR SCREEN: Negative

ADAMTS13 BETHESDA TITER: <0.4 BU

  

Less than 10% ADAMTS-13 activity is highly indicative of thrombotic thrombocytopenic purpura (TTP) in an appropriate clinical setting. The presence of ADAMTS-13 inhibition (positive inhibitor screen) with a measurable antibody titer is most consistent with an acquired TTP.

Billing

  
85397
85335 (if appropriate)

Tracking

  
05/31/2022
  
07/31/2022
  
06/07/2022